Lake Nona Archives - Sanford Burnham Prebys
Institute News

Parkinson’s research benefits from powerful collaboration

AuthorDeborah Robison
Date

June 19, 2017

Medical discoveries may languish in laboratories for years without the necessary tools and means to drive findings further toward the development of novel therapeutics. This could have been the case for Dr. Pamela McLean, a Parkinson’s disease expert at the Mayo Clinic in Jacksonville, Fla., had a collaboration with SBP’s drug discovery team in Lake Nona not emerged.

McLean’s deep clinical experience and unique insights into the molecular basis of the disease, combined with SBP’s screening technology and drug discovery expertise, produced promising findings and attracted a significant grant from The Michael J. Fox Foundation (MJFF). Just recently, the researchers were awarded a special MJFF bridge grant to ensure that the science continues to move forward.

McLean studies the role of alpha-synuclein, a protein that misfolds and aggregates in the brain regions that are critically involved in Parkinson’s disease. She brought her cell-based models of alpha-synuclein protein “clumping” to SBP where the drug discovery team screened through 800,000 chemical compounds for substances that were capable of removing the abnormal protein and protecting the cells. Results from the initial study identified eight compounds as potential inhibitors of alpha-synuclein aggregation.

“Our current investigation will enhance the effectiveness of the drug candidates that we previously identified and advance them to pre-clinical development on the road to patient treatment,” said Dr. Layton Smith, director of SBP at Lake Nona Drug Discovery.

During this phase, chemistry teams will validate and refine the drug candidates’ biological activities. The process will likely eliminate some candidates in a testing funnel designed to narrow the compounds to those that exhibit the desired properties, such as inhibiting protein aggregation in the brain. Concurrently, McLean will explore the drug candidates’ mechanism of action to understand if the compounds work by blocking aggregation, enhancing removal of the clumps or by some other means. New therapies are critically needed to treat the more than 1 million Americans afflicted with Parkinson’s disease. Current medicines treat symptoms but do not reverse the effects of the disease.

Institute News

On the map: doing business in Medical City

AuthorKyle Ziegler
Date

April 13, 2017

More than a hundred central Florida business leaders gathered in Lake Nona’s Medical City to learn about the latest life sciences and health innovations during Orlando Business Journal’s “Doing Business in Medical City” event on April 13, 2017. Leaders from anchor institutions Guidewell Innovation Center, Nemours Children’s Hospital, Sanford Burnham Prebys Medical Discovery Institute (SBP) and Tavistock touted numerous examples of collaborations and tech innovations all unique to the area’s health ecosystem.

Panelists highlighted several important collaborative projects taking shape inside of Medical City research labs. “The way we approach basic science and biomedical discovery is through interaction,” said Layton Smith, PhD, director of drug discovery and pharmacology at SBP. “We need to be—and are—interacting with partners like the University of Central Florida, the University of Florida and more. So essentially, what we’ve built here is a node in a network of biomedical research.” One of the recent collaborations he described involves a project with UCF researchers on Zika. Also discussed was an ongoing partnership with the Mayo Clinic and the Michael J. Fox Foundation on personalized medicine approaches for Parkinson’s disease.

Panelists also emphasized the role of people partnerships in broadening community health and wellness initiatives in the area.

Jim Zboril, president of Tavistock Development Co. LLC, described collaboration as a hallmark of Lake Nona and highlighted the built environment as a foundation for residents to live, work, and play. The Lake Nona Life Project, for example, allows “citizen scientists” who live and work in Lake Nona to take part in research studies happening in their backyard. He also provided a glimpse of the latest projects taking place inside of Lake Nona Town Center, which will include a new fitness center and cable water park, as well as new developments in the adjacent Lake Nona Sports and Performance District, which is home to the USTA’s National Campus and Orlando City Soccer’s training facility.

Additionally, new tech innovations are fast-tracking a “wellness without walls” approach to healthcare delivery. Renee Finley, president of GuideWell Innovation, described how new wearable sensor technology displayed in Lake Nona’s intelligent home WHIT (Wellness, Health, Innovation, and Technology), can track activities of daily living, including how many times the refrigerator is opened in a day and movements in the home. ‘Those things can be indicators of other health conditions,” she said.

Meanwhile, Nemours’ telehealth services are making the demand for access to healthcare easier by providing a gateway for the consumer to get in touch with a specialist. “We have an app where you can access any one of our pediatric providers for urgent consultation any time of the day or night—24/7,” said Andre Hebra, MD, chief medical officer of Nemours Children’s Hospital. “And beyond that, we have telehealth services to provide specialty consultations to some of our partnership hospitals.”

Institute News

Florida Translational Research Program funding re-fuels drug discovery collaborations with leading research institutions

AuthorDeborah Robison
Date

January 18, 2017

Reinstatement of Florida Translational Research Program (FTRP) funding has provided scientists at Florida universities and medical research institutes with renewed access to the world-class drug discovery technology housed within Sanford Burnham Prebys Medical Discovery Institute at Lake Nona (SBP). The FTRP offers investigators the chance to work with drug discovery experts to translate their research advances into potential new medicines. The facility’s high-tech resources, including high-throughput robotics that screen tens of thousands of chemical compounds per day, combined with expert advice from faculty that have decades of experience in the pharmaceutical industry, make for powerful collaborations that benefit the statewide life science industry.

Funded by the state of Florida and administered by SBP, the program’s most recent call for proposals netted 16 projects—some new and some ongoing—from all Florida universities with biomedical research programs, including the University of Florida, Florida State, Florida International University, University of Central Florida, University of South Florida and University of Miami, as well as the Mayo Clinic and Moffitt Cancer Center.  

All projects focus on major unmet medical needs: aggressive cancers, Alzheimer’s, diabetes, heart disease and drug-resistant infections. While some teams are testing drug libraries to find compounds with desired properties, others are refining active compounds for potency and specificity. The collaborations aim to identify drug candidates with clinical benefits such as reducing tumor size, halting aggressive breast cancer metastasis, reducing inflammation in diseased brains or treating antibiotic-resistant pathogens.

“Our intent is to replicate success stories like that of Pamela McLean, associate professor of neuroscience at the Mayo Clinic,” says Layton Smith, PhD, director of drug discovery at SBP’s Lake Nona campus. “The initial results from her FTRP project led to her receiving the biggest grant ever awarded by the Michael J. Fox Foundation. Similarly, our work with Kirk Conrad, professor of physiology at the University of Florida on a potential heart failure drug has attracted the interest of a major pharmaceutical company.”

“Our approach to collaborative drug discovery has brought more research funding to the state,” adds Smith. “But more important, our work may lead to new therapeutics that reduce the burden of disease around the world.”

Institute News

Simulation matters at Lake Nona Research Day, from cells to big data

AuthorCommunications
Date

October 14, 2016

Scientists, physicians and trainees recently gathered at the first Lake Nona Research Day to share the latest research and technologies that are contributing to innovations in health care.. The event brought together senior and junior practitioners from Medical City’s five institutions.

“As we planned the symposium, we decided to focus on the trainees, who then became the glue that brought everything together,” said Philip Wood, D.V.M., PhD, director of academic affairs at Sanford Burnham Prebys Medical Discovery Institute (SBP) at Lake Nona and chair of the Medical City Research Council. “Their enthusiasm to share their science is evident in the 120 research posters that highlight the research emerging from SBP, the University of Central Florida, the University of Florida, Nemours Children’s Hospital, and the Orlando VA Medical Center.” The symposium was presented by the Lake Nona Institute.

Disease modeling by high-tech simulation and data mining were themes of featured talks. Lawrence Lesko, PhD, professor, Center for Pharmacometrics at UF, described using biosimulation to project drug performance in virtual patients. “What we do is like a flight simulator—we evaluate drug impact before testing in patients, frequently focusing on drug-drug interactions,” said Lesko.   

Similarly, Daniel Kelly, MD, scientific director of SBP at Lake Nona, spoke about his lab’s work to study the changes in mitochondria function that are seen in heart failure patients and to simulate disease in a dish using human induced pluripotent stem cell-derived cardiomyocytes.  “We need to become mitochondrial doctors to treat heart failure,” said Kelly. “These models will help us discover therapeutic approaches tailored to the etiology of a subset of heart failure cases that could be given earlier than current treatments.”

Steven Kern, PhD, deputy director, Quantitative Sciences at the Bill and Melinda Gates Foundation, delivered the keynote on using data to decide how to invest $1 billion in precision public health projects on a global scale. “We build drug-disease models to determine how to prevent epidemics like malaria. In our Healthy Birth and Growth Project, we model real-world data to determine the right interventions, in the right dosage, to get the right response—to get children to the healthiest stage at 100 days of life,” explained Kern. 

David Odahowski, president and CEO of the Edyth Bush Charitable Foundation, which sponsored the symposium, concluded the program by observing that innovation often comes from the intersection of disciplines. “I think what we learned today is that collaboration is the true measure of success and that is especially true here in Medical City.”

Institute News

Breakthrough in understanding how stem cells become specialized

AuthorJessica Moore
Date

August 4, 2016

Scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) have made a major advance in understanding how the cells of an organism, which all contain the same genetic information, come to be so diverse. A new study published in Molecular Cell shows that a protein called OCT4 narrows down the range of cell types that stem cells can become. The findings could impact efforts to produce specific types of cells for future therapies to treat a broad range of diseases, as well as aid the understanding of which cells are affected by drugs that influence cell specialization.

“We found that the stem cell-specific protein OCT4 primes certain genes that, when activated, cause the cell to differentiate, or become more specialized,” said Laszlo Nagy, MD, PhD, professor and director of the Genomic Control of Metabolism Program at SBP’s Lake Nona campus and senior author of the study. “This priming customizes stem cells’ responses to signals that induce differentiation and makes the underlying genetic process more efficient.”

Differentiation matters

As an organism—such as a human—develops from its simplest, earliest form into maturity, its cells transition from a highly flexible state—stem cells—to more specialized types that make up its tissues. Many labs are trying to recapitulate this process to generate specific types of cells that could be transplanted into patients to treat disease. For example, pancreatic beta cells could treat diabetes, and neurons that produce dopamine could treat Parkinson’s.

What OCT4 does

OCT4 is a transcription factor—a protein that regulates gene activity—that maintains stem cells’ ability to give rise to any tissue in the body. OCT4 works by sitting on DNA and recruiting factors that either help initiate or repress the reading of specific genes.

The new study shows that, at certain genes, OCT4 also collaborates with transcription factors that are activated by external signals, such as the retinoic acid (vitamin A) receptor (RAR) and beta-catenin, to turn on their respective genes. Vitamin A converts stem cells to neuronal precursors, and activation of beta-catenin by Wnt can either support pluripotency or promote non-neural differentiation, depending on what other signals are present. Recruitment of these factors ‘primes’ a subset of the genes that the signal-responsive factors can activate.

The big picture

“Our findings suggest a general principle for how the same differentiation signal induces distinct transitions in various types of cells,” added Nagy. “Whereas in stem cells, OCT4 recruits the RAR to neuronal genes, in bone marrow cells, another transcription factor would recruit RAR to genes for the granulocyte program. Which factors determine the effects of differentiation signals in bone marrow cells—and other cell types—remains to be determined.”

Next steps

“In a sense, we’ve found the code for stem cells that links the input—signals like vitamin A and Wnt—to the output—cell type,” said Nagy. “Now we plan to explore whether other transcription factors behave similarly to OCT4—that is, to find the code in more mature cell types.

“If other factors also have this dual function—both maintaining the current state and priming certain genes to respond to external signals—that would answer a key question in developmental biology and advance the field of stem cell research.”

The paper is available online here.

Institute News

Aspiring scientists tackle big data at Sanford Burnham Prebys Medical Discovery Institute

AuthorGuest Blogger
Date

June 24, 2016

Growing up, Courtney Astore was inquisitive about science and technology. So when she had the opportunity to participate in middle school science fairs, she jumped at the chance. In high school, Astore’s research in behavioral and social science, medicine and elaborate statistical algorithms led to her being a finalist at the Intel International Science and Engineering Fair three times.

Today, as an incoming sophomore at the University of Central Florida (UCF), Astore is majoring in Biotechnology with a focus on Bioinformatics. Together, with her lifelong friend Rebecca Elsishans at the University of Florida, she plans to launch a start-up company called Enasci-x that will use genetic analysis to aid in vaccine development.

Executives at UCF’s business incubator contacted Leslie Molony, PhD, senior director of Business Development for Sanford Burnham Prebys Medical Discovery Institute’s (SBP)  Lake Nona campus to inquire about providing  training to aspiring scientists enrolled in the National Science Foundation- iCorps™ funded  LaunchPad program.

The LaunchPad program fosters entrepreneurial research designed to help the commercialization of technology. Molony guided Astore and Elsishans in the biological science and business aspects of forming a start-up for their first product-in-development called Genes4Vaccines.

Her students received guidance on a top-level list of ‘how-to’s’

  • how to understand protein structures
  • how to generate data that can lead to new drug discovery
  • how to define new products and commercialize them
  • how to develop business plans and ‘pitching’ strategies

“Courtney and Rebecca are phenomenal young women who are very eager to understand how the medical research process—vaccine discovery–can lead to commercial products,” said Molony.  “They have great potential to become software service providers, or to use their talents to discover new vaccine targets that may lead to partnerships with pharmaceutical companies.”

“In terms of where we are today and how we’ve been able to map out what we need to do, we couldn’t have done any of this without Dr. Molony,” said Astore. “Her drug discovery background and business development expertise have opened our eyes to the potential of what we can accomplish, and what we need to do to get there. We know our next big steps are to finalize our minimum value product, get data validation in the lab and then attract investors.”

Big data for medical research, adds Molony, is a growing niche in the field of infectious disease where vaccine and therapy needs arise quickly and unexpectedly.

To augment her student’s training, she connected Astore with Fraydoon Rastinejad, PhD, professor in SBP’s Center for Metabolic Origins of Disease at Lake Nona who offered her a summer internship where she’ll be collecting data and analyzing human disease databases.

“Dr. Rastinejad is one of the most renowned researchers in the field, and I’m honored to have the opportunity to work with him.  My internship will give me a deeper base of scientific knowledge to advance my research,” said Astore. “To work hands-on in his lab, analyzing data that recognizes patterns and clues to disease development is a dream come true.”

This post was written by Jackie Kelvington

Related:
Genes4Vaccines – UCF I-Corps

Institute News

SBP seeks renewed funding for Florida Translational Research Program to ensure breakthrough discoveries continue

Authorjmoore
Date

February 18, 2016

The Florida Translational Research Program (FTRP), an early drug discovery initiative funded by the state of Florida, has proven crucial in advancing research and securing out-of-state funding for investigators at SBP and collaborating institutions. During the current legislative session, SBP is seeking renewed funding of the three-year program after a budget hiatus in 2015 put numerous investigations on hold. Continue reading “SBP seeks renewed funding for Florida Translational Research Program to ensure breakthrough discoveries continue”

Institute News

New links between heart hormones, obesity, and diabetes

AuthorGuest Blogger
Date

February 17, 2016

New research from SBP’s Sheila Collins, PhD, and Richard Pratley, MD, has revealed an important relationship between proteins secreted by the heart and obesity, glucose intolerance, and insulin resistance. The findings, published in Obesity, offer a new approach to treating metabolic disorders, including type 2 diabetes, by targeting the pathway that controls the proteins’ concentration in the blood. Continue reading “New links between heart hormones, obesity, and diabetes”

Institute News

Leading cardiometabolic researcher to join SBP

Authordrobison
Date

November 5, 2015

The cardiovascular researcher who pioneered visualizing the function of the human heart using the most powerful magnetic resonance available will soon join SBP’s Florida campus. E. Douglas Lewandowski, PhD, will become professor in the Cardiovascular Metabolism Program and director of Cardiovascular Translational Research starting December 2015. He is among the most preeminent investigators in the world who specialize in the metabolic basis of heart failure, including ischemic heart disease and diabetic cardiomyopathy.

“Doug Lewandowski’s pioneering work has unveiled new concepts and therapeutic strategies aimed at improving the treatment of heart failure, a worldwide health problem. He will continue this work at SBP, leading an innovative bench-to-clinic research program at SBP and the Florida Hospital Translational Research Institute for Metabolism and Diabetes (TRI-MD). His recruitment is transformational for our translational research efforts in the cardiovascular arena,” said Daniel P. Kelly, MD, Tavistock Distinguished Professor and scientific director, Center for Metabolic Origins of Disease at SBP Lake Nona.

Lewandowski’s contributions to understanding metabolic pathways and fuels that may protect against the high-morbidity, -mortality, and economic health burden of heart failure are recognized as among the most rigorous and field-advancing. He is renowned in the use of nuclear magnetic resonance (NMR) spectroscopy to visualize and measure metabolic activity in the intact beating heart in health and disease. His expertise in medical imaging techniques involves manipulation of metabolic activity in the ailing heart with pharmacological agents and targeted gene manipulation.

He will hold a joint appointment at Florida Hospital as senior principal investigator at the TRI-MD. He views the partnership between SBP’s basic research and the TRI’s clinical investigations as an attractive and effective research model that will accelerate the translation of the fundamental mechanisms of heart disease and therapeutic targets toward patient-based studies to identify new treatments, therapeutics, and cures.

“With Lake Nona’s emphasis and existing expertise in cardiometabolic disease, I feel that I can immediately contribute to team science approaches to elucidate fundamental mechanisms of heart and metabolic disease. My focus will be to translate findings in SBP’s laboratories to human studies of the metabolic basis of heart disease at the TRI,” said Lewandowski. “It is this partnership that I anticipate will be a game changer in the way I will be able to implement the translation of my laboratory investigations, and I find this very, very exciting.”

Prior to joining SBP, Lewandowski held the position of professor in the Department of Physiology and Biophysics, in the Department of Medicine, and director of the Program in Integrative Cardiac Metabolism at the University of Illinois at Chicago. Previously, Dr. Lewandowski spent a decade on the faculty at Harvard Medical School with hospital appointments at Massachusetts General Hospital in Boston, Mass.